The Fort Worth Press - Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

USD -
AED 3.672503
AFN 63.999817
ALL 82.450149
AMD 357.809202
ANG 1.790403
AOA 917.499877
ARS 1549.874098
AUD 1.484483
AWG 1.8025
AZN 1.701804
BAM 1.7757
BBD 2.012982
BDT 124.44505
BGN 1.77347
BHD 0.377199
BIF 3005
BMD 1
BND 1.288366
BOB 11.659547
BRL 5.782163
BSD 0.99941
BTN 93.823002
BWP 13.990966
BYN 3.003223
BYR 19600
BZD 2.010077
CAD 1.429775
CDF 2318.000248
CHF 0.839835
CLF 0.025358
CLP 998.039782
CNY 6.66455
CNH 6.664155
COP 3318.97
CRC 445.37243
CUC 1
CUP 23.986201
CVE 100.374973
CZK 22.19355
DJF 177.719967
DKK 6.79487
DOP 60.550244
DZD 137.065944
EGP 53.6853
ERN 15
ETB 161.249886
EUR 0.90898
FJD 2.28475
FKP 0.756558
GBP 0.758315
GEL 2.594973
GGP 0.756558
GHS 11.734977
GIP 0.756558
GMD 73.500352
GNF 8859.999657
GTQ 7.63916
GYD 209.138162
HKD 7.84625
HNL 27.06947
HRK 6.831965
HTG 130.99394
HUF 330.970967
IDR 18279
ILS 3.24365
IMP 0.756558
INR 93.93975
IQD 1515
IRR 1925254.000425
ISK 124.339896
JEP 0.756558
JMD 158.482001
JOD 0.709041
JPY 159.416016
KES 130.039708
KGS 87.449402
KHR 4080.000054
KMF 447.50406
KPW 900.00035
KRW 1336.365011
KWD 0.31162
KYD 0.833012
KZT 444.73296
LAK 22524.999912
LBP 89550.0002
LKR 332.650884
LRD 168.501261
LSL 16.984982
LTL 2.95274
LVL 0.60489
LYD 6.455006
MAD 9.99725
MDL 18.281771
MGA 4594.000024
MKD 55.947457
MMK 2099.568705
MNT 3604.028735
MOP 8.07799
MRU 40.649826
MUR 47.819509
MVR 15.410198
MWK 1737.000365
MXN 18.52304
MYR 4.094017
MZN 63.910219
NAD 16.984964
NGN 1345.879753
NIO 36.750192
NOK 9.655665
NPR 150.11644
NZD 1.81763
OMR 0.384501
PAB 0.999532
PEN 3.408199
PGK 4.513966
PHP 63.918496
PKR 276.374515
PLN 4.001145
PYG 6202.732761
QAR 3.644022
RON 4.857802
RSD 106.930999
RUB 82.598883
RWF 1477
SAR 3.763042
SBD 8.098361
SCR 13.860567
SDG 601.548038
SEK 10.094865
SGD 1.288925
SHP 0.758581
SLE 23.04986
SLL 20969.503664
SOS 572.511276
SRD 37.453496
STD 20697.981008
STN 22.375
SVC 8.745744
SYP 13002.000337
SZL 16.984982
THB 33.885502
TJS 9.210795
TMT 3.51
TND 3.041994
TOP 2.40776
TRY 50.421202
TTD 6.787708
TWD 32.977904
TZS 2644.992965
UAH 45.435091
UGX 4147.791748
UYU 40.582868
UZS 12024.999857
VES 914.603597
VND 25764
VUV 120.719595
WST 2.810584
XAF 596.252115
XAG 0.021223
XAU 0.000259089508
XCD 2.70255
XCG 1.801394
XDR 0.707052
XOF 596.252115
XPF 108.875027
YER 236.501049
ZAR 16.96925
ZMK 9001.199115
ZMW 20.4664
ZWL 321.999592
SSP 5945.381189
MXV 2.078532
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85%

Crofelemer, approved by the FDA under the brand name Mytesi® for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhea, cancer therapy-related diarrhea, and IBS

Crofelemer could have a significant supportive impact on GLP-1 therapies, one of the fastest growing classes of drugs, estimated to be a $56 billion global market in 2025 and projected to grow at a CAGR of 21% to $322 billion 20341

Text size:

SAN FRANCISCO, CA / ACCESS Newswire / January 29, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced Napo's filing of a broad defining provisional patent application with the U.S. Patent and Trademark Office (USPTO) for crofelemer, Jaguar's novel plant-based FDA-approved gastrointestinal normalizing prescription drug, to mitigate the gastrointestinal side effects associated with glucagon-like peptide-1 (GLP-1) receptor agonists and antagonists, together with other incretin-based therapies including glucose-dependent insulinotropic polypeptide (GIP) agonists and antagonists, and glucagon-agonist drugs.

GLP-1 and GIP drugs are analogs for incretin hormones that are released by the gut and bind to receptors in the brain and gastrointestinal tract, suppressing appetite, which consequently leads to body weight loss.

"Gastrointestinal disorders were the most frequently reported adverse effects during clinical trials and real-world experience of GLP-1 receptor agonists, 2 such as semaglutide, tirzepatide, and liraglutide. GI adverse events usually develop in 40-70% of patients treated with GLP-1 receptor agonists, although they have sometimes been reported in up to 85%, 3 which can lead to dose limitations or dose discontinuations. There are also numerous investigative agents, including incretins and combinations with GLP-1 drugs, both as receptor agonists and antagonists, all of which are associated with significant GI side effects, often in a dose-dependent manner. Our IP strategy includes claims for both commercialized obesity drugs and incretin-based therapies in development. Crofelemer, approved by the U.S. Food and Drug Administration under the brand name Mytesi for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhea, cancer therapy-related diarrhea, and IBS," said Lisa Conte, Jaguar's founder, president, and CEO. "Crofelemer has a safety profile supporting its chronic utilization, and we are excited about crofelemer's possible potential to normalize specific GI side effects associated with obesity therapies, address patient comfort, and help patient's stay on their therapy."

About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi ® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that crofelemer could have a significant supportive impact on GLP-1 therapies, and Jaguar's expectation that crofelemer may have the potential to normalize specific GI side effects associated with obesity therapies, address patient comfort, and help patient's stay on their therapy. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

1 GLP-1 Analogues Market Outlook: Rapid Growth at 21.3% CAGR to Surpass USD 322.85 Billion by 2034 | PMR

2 Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, Zhang Y, Ji L, Wang J, Shi L. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17(1):35-42. doi: 10.1089/dia.2014.0188

3 J Clin Med. 2022 Dec 24;12(1):145. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus

CONTACT:
[email protected]
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

C.M.Harper--TFWP